ASX-listed health tech firm CardieX announced it acquired Silicon Valley-based Blumio, a developer of cardiovascular sensor algorithms and data analytics tools.
CardieX focuses on hypertension, cardiovascular health and other arterial health disorders, while Blumio develops wearable-sensor technologies focused on capturing cardiovascular data, including blood pressure measurements.
The acquisition follows a three-year collaboration between the companies, which determined Blumio’s sensor technology was compatible with CardieX subsidiary ATCOR’s SphygmoCor arterial technology that measures the central aortic pressure waveform.
CardieX will also utilize Blumio’s assets to improve its Arty Heart Health Analytics Platform in its CONNEQT Pulse and for its CONNEQT Band devices.
“Blumio brings a suite of capabilities in wearable sensor development, signal processing and big data analytics expertise that will benefit both of our ATCOR and CONNEQT brands, especially in relation to the ongoing development activities surrounding our CONNEQT Band. This acquisition is a natural extension of our core solutions that provide a comprehensive ecosystem of unique health and wellness features focused on heart health,” CardieX Group CEO Craig Cooper said in a statement.
THE LARGER TREND
CardieX adds Blumio to its group of companies with a number of patented healthcare technologies.
In March, CardieX and AI-enabled wearable company, Mobvoi, announced the launch of its TicWatch GTH Pro, which leverages aspects of ATCOR’s heart health monitoring SphygmoCor technology.